Research Topics
Species | Leon A AdamsSummaryAffiliation: University of Western Australia Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver diseaseLeon A Adams
School of Medicine and Pharmacology, The University of Western Australia, Western Australia, Australia
J Gastroenterol Hepatol 26:1536-43. 2011..We therefore compared the accuracy of simple bedside versus complex fibrosis models across a range of fibrosis in a multi-centre NAFLD cohort...- NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up studyLeon A Adams
School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, Australia
Am J Gastroenterol 104:861-7. 2009..We sought to determine whether NAFLD with elevated aminotransaminase (ALT) levels was a risk factor for incident diabetes or the metabolic syndrome (MS) over an 11-year period... - Ganciclovir and the treatment of Epstein-Barr virus hepatitisLeon A Adams
Department of Gastroenterology and Hepatology, Sir Charles Gardiner Hospital, Nedlands, WA, Australia
J Gastroenterol Hepatol 21:1758-60. 2006..Herein, the successful use of ganciclovir in two immunocompetent patients with severe EBV hepatitis is reported... - Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumptionLeon A Adams
School of Medicine and Pharmacology, Fremantle Hospital Campus, The University of Western Australia, Fremantle, Australia
J Gastroenterol Hepatol 23:1089-93. 2008..The relative effects of obesity compared to alcohol on liver injury are uncertain. We examined their effects on alanine aminotransferase (ALT) and gamma glutamyltransferase (GGT) levels in a population-based cohort... - Biomarkers of liver fibrosisLeon A Adams
School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, Australia
J Gastroenterol Hepatol 26:802-9. 2011..Novel proteins identified by proteomic technology and genetic polymorphisms from genome association studies offer the possibility for further refinement and individualization of biomarker fibrosis models in the future... - Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatmentBriohny W Smith
School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, University of Western Australia, Nedlands, WA 6009, Australia
Nat Rev Endocrinol 7:456-65. 2011.... - Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infectionLeon A Adams
Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, Australia
Clin Chem 51:1867-73. 2005..5 had 74% specificity and 88% sensitivity for advanced fibrosis. CONCLUSIONS: A model of 4 serum markers plus age and sex provides clinically useful information regarding different fibrosis stages among hepatitis C patients... - Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver diseaseOyekoya T Ayonrinde
School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
Hepatology 53:800-9. 2011..The male phenotype of NAFLD is associated with more adverse metabolic features and greater visceral adiposity than the female phenotype despite the lower prevalence of NAFLD... - Nonalcoholic steatohepatitis: risk factors and diagnosisLeon A Adams
School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital Unit, Nedlands, WA 6009, Australia
Expert Rev Gastroenterol Hepatol 4:623-35. 2010..Routine liver aminotransaminase levels are not reliable; however, novel plasma hepatocyte apoptosis markers, either alone or in combination with clinical risk factors, are potential noninvasive diagnostic tools for the future... - Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virusSilvia Lee
Department of Microbiology and Infectious Disease, Royal Perth Hospital, University of Western Australia, Perth, Australia
Dis Markers 28:273-80. 2010..003 relative to Hepascore). Whilst this was only marginally more effective than predictions based on HCV genotype age and sex (p=0.07), it associates high TGFbeta1 and low IP-10 levels with a failure of therapy... - Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort studyLeon A Adams
School of Medicine and Pharmacology, The University of Western Australia, Perth, Western Australia, Australia
Am J Gastroenterol 105:1567-73. 2010..We sought to determine whether a diagnosis of NAFLD influenced mortality among a community-based cohort of patients with type II diabetes mellitus... - Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitisLeon A Adams
School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital Unit, Nedlands, Western Australia, Australia
J Dig Dis 12:10-6. 2011..This review provides a concise overview of the role non-invasive diagnostic tools for the differentiation of fatty liver from NASH as well as for the determination of presence and extent of fibrosis... - Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver diseaseLeon A Adams
School of Medicine and Pharmacology, The University of Western Australia, Liver Transplant Unit, Sir Charles Gairdner Hospital, Nedlands, Australia
Clin Liver Dis 11:25-35, viii. 2007.... - Nonalcoholic fatty liver diseaseLeon A Adams
School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital Campus, Australia
Ann Epidemiol 17:863-9. 2007..Management is further complicated by the inability to predict which patients will develop liver-related morbidity and thus benefit from treatment... - Non-alcoholic fatty liver diseaseBriohny W Smith
School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, University of Western Australia, Nedlands, Australia
Crit Rev Clin Lab Sci 48:97-113. 2011.... - Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasiaAndrew Mitchell
Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Australia
Liver Transpl 14:210-3. 2008..Bevacizumab may potentially alleviate the need for liver transplantation in this group of patients... - Screening for HFE and iron overloadJohn Ombiga
Department of Gastroenterology, Fremantle Hospital, Fremantle, Western Australia, Australia
Semin Liver Dis 25:402-10. 2005..Potential ethical, legal, and psychosocial issues arising through application of genetic screening programs also must be resolved prior to implementation of general population screening programs... - The trials and tribulations of the treatment of nonalcoholic fatty-liver diseaseSeng Khee Gan
Metabolic Research Centre, School of Medicine and Pharmacology, Royal Perth Hospital Unit, Australia, University of Western Australia, Perth, Australia
Curr Opin Lipidol 19:592-9. 2008..To review published clinical trials, with a focus on those of randomized design, of the management of nonalcoholic fatty-liver disease (NAFLD), an increasing complication of the obesity epidemic... - Nonalcoholic fatty liver disease and diabetes mellitusLeon A Adams
School of Medicine, The University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia
Endocr Res 32:59-69. 2007 - Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunctionLeon A Adams
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
Hepatology 39:909-14. 2004..The novel evidence that hypothalamic/pituitary dysfunction may be accompanied by progressive NAFLD has important implications for the work-up and management of patients with hypothalamic/pituitary disease... - Treatment of hyperlipidemia in nonalcoholic fatty liver disease: fat for thoughtLeon A Adams
Indian J Gastroenterol 23:127-8. 2004 - A pilot trial of pentoxifylline in nonalcoholic steatohepatitisLeon A Adams
Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Am J Gastroenterol 99:2365-8. 2004..62) or albumin (4.0 +/- 0.2 vs 4.2 +/- 0.3, p= 0.41). CONCLUSIONS: Aminotransferase levels among patients with NASH improve with administration of pentoxifylline. Strategies to overcome side effects will be needed for future trials... - Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?Leon A Adams
Clin Gastroenterol Hepatol 2:1059-60. 2004 - The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsiesLeon A Adams
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Hepatol 42:132-8. 2005..Changes of aminotransferases do not parallel changes in fibrosis stage. Diabetic patients with elevated BMI and low fibrosis stage are at risk for higher rates of fibrosis progression... - Nonalcoholic fatty liver diseaseLeon A Adams
Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, Minn 55905, USA
CMAJ 172:899-905. 2005..In this article we discuss the etiology, pathogenesis and diagnosis of nonalcoholic fatty liver disease as well as approaches to its management... - The bulge, booze, and the liverLeon A Adams
Clin Gastroenterol Hepatol 3:1195-7. 2005 - Diagnostic evaluation of nonalcoholic fatty liver diseaseLeon A Adams
Division of Gastroenterology and Hepatology, Mayo Clinic and College of Medicine, Rochester, MN 55905, USA
J Clin Gastroenterol 40:S34-8. 2006..Clinical features, particularly diabetes, obesity, and older age, can aid in stratifying patients at risk for advanced fibrosis but are not sufficiently accurate to replace liver biopsy... - Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacyLeon A Adams
Am J Gastroenterol 98:2348-50. 2003